ScreenerHero

FRNMFreenome Inc. Common stock

NAS · US · Healthcare · Diagnostics & Research · freenome.com
13.81USD+1.32%Mkt Cap: 1.47B $P/E: —

Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$232.67BUSDP/E 33.9
DHR
Danaher Corporation
$153.85BUSDP/E 39.0
LONN
Lonza Group Ltd
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$47.86BUSD
A
Agilent Technologies, Inc.
$44.91BUSDP/E 31.9
IDXX
IDEXX Laboratories, Inc.
$43.93BUSDP/E 39.1
IQV
IQVIA Holdings Inc
$42.77BUSDP/E 32.3
WAT
Waters Corporation
$40.32BUSDP/E 103.5
ILMN
Illumina, Inc.
$33.13BUSDP/E 41.0
MTD
Mettler-Toledo International, Inc.
$27.96BUSDP/E 31.5
LH
Labcorp Holdings Inc.
$27.28BUSDP/E 27.8
DGX
Quest Diagnostics Incorporated
$26.97BUSDP/E 26.0
GH
Guardant Health, Inc.
$22.91BUSD
MEDP
Medpace Holdings, Inc.
$17.33BUSDP/E 36.4
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$14.09BUSD
RVTY
Revvity Inc. Common Stock
$13.92BUSDP/E 59.7
ICLR
ICON Public Limited Company
$13.29BUSDP/E 269.1
BIM
bioMerieux S.A.
$9.55BUSDP/E 19.1
TWST
Twist Bioscience Corp.
$9.13BUSD
HeadlineSourceTime
Older
Freenome (FRNM) Climbed, But What Is Driving Attention Now?

Freenome stock reaction and recent performance snapshot Freenome (FRNM) has drawn fresh investor attention following its recent share price move, with the stock last closing at $11.62. This puts the company’s market value at about $1.26b. Over the past month, Freenome’s share price return is 7.59%, while the past 3 months show a 2.83% gain. The stock’s 1 year total return stands at 9.93%, and the year to date performance reflects a decline of 10.62%. Freenome reported revenue of $34.24m,...

Simply Wall St.
Guardant Health, Stock Of The Day, Spikes After Hiking 2026 Outlook

Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. GH stock popped nearly 7% in extended Thursday trading. Health and biotech stocks are acting well in the current market.

Investor's Business Daily